4.7 Article

Activities of mixed NOP and μ-opioid receptor ligands

期刊

BRITISH JOURNAL OF PHARMACOLOGY
卷 153, 期 3, 页码 609-619

出版社

WILEY
DOI: 10.1038/sj.bjp.0707598

关键词

nociceptin; N/OFQ; opioid receptor; NOP; buprenorphine; mouse vas deferens; antinociception

资金

  1. NIDA NIH HHS [R01 DA027811, R01 DA014026, DA14026, R01 DA014026-06] Funding Source: Medline

向作者/读者索取更多资源

Background and purpose: Compounds that activate both NOP and mu-opioid receptors might be useful as analgesics and drug abuse medications. Studies were carried out to better understand the biological activity of such compounds. Experimental approach: Binding affinities were determined on membranes from cells transfected with NOP and opioid receptors. Functional activity was determined by [S-35] GTP gamma S binding on cell membranes and using the mouse vas deferens preparation in vitro and the tail flick antinociception assay in vivo. Key results: Compounds ranged in affinity from SR14150, 20-fold selective for NOP receptors, to buprenorphine, 50-fold selective for mu-opioid receptors. In the [S-35] GTP gamma S assay, SR compounds ranged from full agonist to antagonist at NOP receptors and most were partial agonists at mu-opioid receptors. Buprenorphine was a low efficacy partial agonist at mu-opioid receptors, but did not stimulate [S-35] GTP gamma S binding through NOP. In the mouse vas deferens, each compound, except for SR16430, inhibited electrically induced contractions. In each case, except for N/OFQ itself, the inhibition was due to mu-opioid receptor activation, as determined by equivalent results in NOP receptor knockout tissues. SR14150 showed antinociceptive activity in the tail flick test, which was reversed by the opioid antagonist naloxone. Conclusions and implications: Compounds that bind to both mu-opioid and NOP receptors have antinociceptive activity but the relative contribution of each receptor is unclear. These experiments help characterize compounds that bind to both receptors, to better understand the mechanism behind their biological activities, and identify new pharmacological tools to characterize NOP and opioid receptors.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Pharmacology & Pharmacy

OREX-1019: A Novel Treatment of Opioid Use Disorder and Relapse Prevention

David R. Maguire, Lisa R. Gerak, Gerta Cami-Kobeci, Stephen M. Husbands, Charles P. France, Barbara Belli, Peter Flynn

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2020)

Article Substance Abuse

The development and validation of a human screening model of tobacco abstinence

Meryem Grabski, H. Valerie Curran, David J. Nutt, Stephen M. Husbands, Stuart G. Ferguson, Marcus R. Munafo

DRUG AND ALCOHOL DEPENDENCE (2020)

Article Pharmacology & Pharmacy

Pharmacological Properties of δ-Opioid Receptor-Mediated Behaviors: Agonist Efficacy and Receptor Reserve

Isaac J. Dripps, Ruizhuo Chen, Amanda M. Shafer, Kathryn E. Livingston, Alexander Disney, Stephen M. Husbands, John R. Traynor, Kenner C. Rice, Emily M. Jutkiewicz

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2020)

Article Neurosciences

Effects of acute and repeated treatment with methocinnamox, a mu opioid receptor antagonist, on fentanyl self-administration in rhesus monkeys

David R. Maguire, Lisa R. Gerak, Jesus J. Sanchez, Martin A. Javors, Alex Disney, Stephen M. Husbands, Charles P. France

NEUROPSYCHOPHARMACOLOGY (2020)

Correction Multidisciplinary Sciences

Structural insights into μ-opioid receptor activation (vol 15, pg 931, 2020)

Weijiao Huang, Aashish Manglik, A. J. Venkatakrishnan, Toon Laeremans, Evan N. Feinberg, Adrian L. Sanborn, Hideaki E. Kato, Kathryn E. Livingston, Thor S. Thorsen, Ralf C. Kling, Sebastien Granier, Peter Gmeiner, Stephen M. Husbands, John R. Traynor, William I. Weis, Jan Steyaert, Ron O. Dror, Brian K. Kobilka

NATURE (2020)

Article Neurosciences

Methocinnamox (MCAM) antagonizes the behavioral suppressant effects of morphine without impairing delayed matching-to-sample accuracy in rhesus monkeys

Vanessa Minervini, Alex Disney, Stephen M. Husbands, Charles P. France

PSYCHOPHARMACOLOGY (2020)

Article Pharmacology & Pharmacy

A novel G protein-biased agonist at the μ opioid receptor induces substantial receptor desensitisation through G protein-coupled receptor kinase

Sam Groom, Nina K. Blum, Alexandra E. Conibear, Alexander Disney, Rob Hill, Stephen M. Husbands, Yangmei Li, Lawrence Toll, Andrea Kliewer, Stefan Schulz, Graeme Henderson, Eamonn Kelly, Chris P. Bailey

Summary: This study confirmed that Compound 1 is a G protein-biased mu agonist that can induce substantial rapid receptor desensitisation in mammalian neurons. However, contrary to previous assumptions, the desensitisation effect of Compound 1 is dependent on G protein-coupled receptor kinase (GRK).

BRITISH JOURNAL OF PHARMACOLOGY (2023)

Review Pharmacology & Pharmacy

Countermeasures for Preventing and Treating Opioid Overdose

Charles P. France, Gerard P. Ahern, Saadyah Averick, Alex Disney, Heather A. Enright, Babak Esmaeli-Azad, Arianna Federico, Lisa R. Gerak, Stephen M. Husbands, Benedict Kolber, Edmond Y. Lau, Victoria Lao, David R. Maguire, Michael A. Malfatti, Girardo Martinez, Brian P. Mayer, Marco Pravetoni, Niaz Sahibzada, Phil Skolnick, Evan Y. Snyder, Nestor Tomycz, Carlos A. Valdez, Jim Zapf

Summary: The only medication available to prevent and treat opioid overdose is naloxone, approved by the FDA nearly 50 years ago. Due to its limitations, a scientific meeting was convened by NIAID/NIH to explore emerging alternative approaches for treating opioid overdose in the event of weaponization of synthetic opioids. This meeting discussed new approaches such as intranasal nalmefene, methocinnamox, covalent naloxone nanoparticles, serotonin receptor agonists, fentanyl-binding cyclodextrin scaffolds, detoxifying biomimetic nanosponge decoy receptors, and antibody-based strategies.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)

Article Pharmacology & Pharmacy

Sex differences in the effect of chronic delivery of the buprenorphine analogue BU08028 on heroin relapse and choice in a rat model of opioid maintenance

Jennifer M. Bossert, E. Andrew Townsend, Lindsay K-P Altidor, Ida Fredriksson, Aniruddha Shekara, Stephen Husbands, Agnieszka Sulima, Kenner C. Rice, Matthew L. Banks, Yavin Shaham

Summary: The study showed that chronic administration of BU08028 reduced the incubation of heroin seeking behavior, but unexpectedly may increase the re-acquisition of heroin self-administration in female rats. In male rats, BU08028 exhibited a selective decrease in extinction responding. Additionally, BU08028 had minimal effects on heroin choice behavior in both sexes.

BRITISH JOURNAL OF PHARMACOLOGY (2022)

Article Pharmacology & Pharmacy

Long-term antagonism and allosteric regulation of mu opioid receptors by the novel ligand, methocinnamox

Joshua C. Zamora, Hudson R. Smith, Elaine M. Jennings, Teresa S. Chavera, Varun Kotipalli, Aleasha Jay, Stephen M. Husbands, Alex Disney, Kelly A. Berg, William P. Clarke

Summary: Opioid overdose is a major cause of death in the United States, with current treatment mainly relying on the competitive antagonist naloxone. However, the short half-life and surmountable antagonism of naloxone limits its effectiveness. Research suggests that the long-lasting, non-surmountable antagonist methocinnamox (MCAM) may offer an improvement in overdose treatment by targeting mu opioid receptors.

PHARMACOLOGY RESEARCH & PERSPECTIVES (2021)

Article Neurosciences

PPL-138 (BU10038): A bifunctional NOP/mu partial agonist that reduces cocaine self-administration in rats

Andrea Cippitelli, Madeline Martinez, Gilles Zribi, Gerta Cami-Kobeci, Stephen M. Husbands, Lawrence Toll

Summary: This study found that PPL-138 effectively reduces cocaine consumption and relapse in rats. The compound increased locomotor activity in female rats but had no effect on food responses in both sexes. The suppression of cocaine self-administration by PPL-138 could be reversed by blocking mu-opioid receptors but not NOP receptors. Additionally, PPL-138 also reduced the reinstatement of cocaine seeking behavior.

NEUROPHARMACOLOGY (2022)

Article Behavioral Sciences

OREX-1038: a potential new treatment for pain with low abuse liability and limited adverse effects

Lisa R. Gerak, David R. Maguire, Gerta Cami-Kobeci, Keith M. Olson, John R. Traynor, Stephen M. Husbands, Charles P. France, Lisette Acevedo, Barbara Belli, Peter Flynn

Summary: This study explores a multifunctional ligand, OREX-1038, targeting mu opioid and nociceptin/orphanin FQ peptide receptors, and confirms its long-acting antinociceptive effects with limited adverse effects.

BEHAVIOURAL PHARMACOLOGY (2022)

Article Biochemistry & Molecular Biology

Opioid Antagonists from the Orvinol Series as Potential Reversal for Overdose

Alex Disney, Keith M. Olson, Amanda M. Shafer, Sierra C. Moore, Jessica P. Anand, John R. Traynor, Stephen M. Husbands

Summary: The study designed and synthesized an orvinol antagonist, 14, which showed no agonist activity in vitro, and was at least equally effective as naloxone in reversing the effects of mu-opioid receptor agonists in vivo.

ACS CHEMICAL NEUROSCIENCE (2022)

Article Chemistry, Analytical

Photochemical Fingerprinting Is a Sensitive Probe for the Detection of Synthetic Cannabinoid Receptor Agonists; toward Robust Point-of-Care Detection

Rachael C. Andrews, Benedict May, Federico J. Hernandez, Gyles E. Cozier, Piers A. Townsend, Oliver B. Sutcliffe, Tom S. F. Haines, Tom P. Freeman, Jennifer Scott, Stephen M. Husbands, Ian S. Blagbrough, Richard W. Bowman, Simon E. Lewis, Matthew N. Grayson, Rachel Crespo-Otero, David R. Carbery, Christopher R. Pudney

Summary: With the prevalence of synthetic cannabinoid receptor agonist (SCRA) use and the emergence of structurally advanced generations, there is a need for advanced drug detection methods. This study demonstrates the potential of fluorescence spectral fingerprinting (FSF) in rapid SCRA detection. The study also shows the sensitivity of FSFs to structural changes and the identification of specific degradation products.

ANALYTICAL CHEMISTRY (2023)

Article Biochemistry & Molecular Biology

Synthetic cannabinoid receptor agonists are monoamine oxidase-A selective inhibitors

Sarah A. Hindson, Rachael C. Andrews, Michael J. Danson, Marc W. van Der Kamp, Amy E. Manley, Oliver B. Sutcliffe, Tom S. F. Haines, Tom P. Freeman, Jennifer Scott, Stephen M. Husbands, Ian S. Blagbrough, J. L. Ross Anderson, David R. Carbery, Christopher R. Pudney

Summary: Synthetic cannabinoid receptor agonists (SCRAs) are rapidly growing recreational drugs with diverse effects and severe side effects. This study hypothesized that SCRAs may act as monoamine oxidase inhibitors (MAOIs) based on their structural similarity and matching clinical outcomes. Through in silico and experimental studies, it was found that SCRAs are MAO-A-specific inhibitors and their affinity varies depending on the nature of the SCRA 'head' group. This research indicates that SCRA activity is not limited to cannabinoid receptor agonism and suggests alternative interactions to explain their diverse side effects.

FEBS JOURNAL (2023)

暂无数据